where do glp 1 drugs come from Evolution of GLP‐1 Receptor Agonists for Diabetes Treatment The GLP-1 Access Gap: Mapping
Description
Sockalingam S, Leung SE, Hawa R, Wnuk S, Parikh SV, Jackson T, et al
This is such an important reminder: GLP-1 therapy can shift physiology, but it cannot replace the foundational habits that protect metabolic health
The difference is that Mounjaro is for diabetes and Zepbound is for weight loss
doi: 10.1210/endo.135.5.7956929
The other factor is that patents for GLP-1s are set to expire in large markets like China, India, Brazil, Canada and Turkey, where 40% of the global population (and roughly 33% of adults considered obese) live
The potential interaction between TRPV1 and GLP-1-derived peptides has been elucidated through structural models
